Gabapentin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Gabapentin: From Anticonvulsant Use to Acne (disease)
One-Sentence Summary
Gabapentin is a gabapentinoid anticonvulsant with well-established international use for partial seizures and neuropathic pain, though no ARTG-registered product was found for it in this evidence pack (Australian market status: Not Marketed). The TxGNN model’s top-ranked prediction for gabapentin is Acne (disease), but this is currently supported only by a single, apparently mismatched case report and no clinical trials — an evidence level of L5 (model prediction only).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not established in this evidence pack (DrugBank original indications and MOA are both data gaps). Literature returned elsewhere in this pack describes gabapentin as an anticonvulsant used for partial/tonic-clonic seizures and neuropathic pain. |
| Predicted New Indication | Acne (disease) |
| TxGNN Prediction Score | 98.46% |
| Evidence Level | L5 |
| Australia Market Status | Not Marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for gabapentin is not available in this evidence pack (flagged as a High-severity data gap). From literature returned elsewhere in this pack, gabapentin is known to bind the α2δ subunit of voltage-gated calcium channels, reducing glutamate/substance P release — a mechanism well established for its anticonvulsant and neuropathic-pain uses, but with no known relevance to acne pathophysiology (sebum production, comedogenesis, or Cutibacterium acnes activity).
For this specific top-ranked prediction, no mechanistic pathway linking gabapentin to acne is provided anywhere in the evidence pack, and no clinical trials were returned. The single literature record retrieved (PMID 22278969) is a case report titled “Unusual case of a swollen painful toe in a young man” — a topic unrelated to both acne and gabapentin’s known pharmacology, and most plausibly a literature-search mismatch rather than genuine supporting evidence.
Given this, the prediction should be treated as a pure knowledge-graph association (TxGNN rank 14,906 of the model’s output) rather than a clinically or mechanistically grounded hypothesis at this stage.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 22278969 | 2012 | Case report (unrelated topic) | Arthritis care & research | Describes a swollen, painful toe in a young man; no abstract available, and the content does not relate to acne or gabapentin — likely a literature-search mismatch rather than supporting evidence. |
Australia Market Information
No ARTG entries were returned for gabapentin in this evidence pack (market status: Not Marketed, total ARTG entries: 0).
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale:
- There are no clinical trials and no credible literature supporting gabapentin for acne — the sole literature match appears to be an indexing/retrieval error, not genuine evidence.
- Evidence level is L5 (model prediction only, decision stage S0); the mechanistic case is unestablished.
To proceed, the following is needed:
- Confirmed mechanism of action data for gabapentin (currently a data gap)
- TGA-approved Product Information / warnings and contraindications (currently a Blocking-severity data gap, required before any S1 safety screening)
- A manual check of whether the acne literature match reflects a genuine record or a search/indexing error, and re-query of PubMed/ClinicalTrials.gov specifically for “gabapentin AND acne”
- Any real preclinical or clinical rationale connecting α2δ calcium-channel modulation to acne pathophysiology before further investment
Note: within this same evidence pack, other candidate indications for gabapentin — notably epilepsy with generalized tonic-clonic seizures and myofascial pain syndrome (both L2, with completed Phase 2/3 trials) — have substantially stronger supporting evidence and may warrant separate evaluation ahead of this acne signal.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.